Pharmacy benefits managers; definitions; contractual duties to provider; prohibitions; reimbursement amounts; effective date.
HB3538 revises Oklahoma law governing pharmacy benefits managers (PBMs) and their contracts with pharmacies and pharmacy service administrative organizations. The bill updates statutory definitions related to acquisition cost, covered entities, PBMs, providers, and related terms, and clarifies that an employer administering its own self-funded health plan is not treated as a PBM unless it directly negotiates with manufacturers, processes claims, or manages its own retail pharmacy network without using a third party.
The bill also strengthens PBM duties in reimbursement and appeals. It requires PBMs to identify the sources used to set maximum allowable cost (MAC) pricing, update MAC lists at least every seven days, and maintain a provider-specific way to access MAC information. It adds detailed appeal procedures for below-cost reimbursement disputes, including deadlines for responses, acceptance of electronic batch appeals, permission for pharmacies to submit additional documentation, and requirements to provide claim-level detail when reimbursement is adjusted. If an appeal is approved, the PBM must allow reversal and rebilling, make the change retroactive for similarly situated claims, and in some cases pay the provider directly if the claim is not reprocessed in time.
HB3538 also limits PBM pricing practices by requiring that drugs placed on a MAC list be FDA-rated therapeutically equivalent products that are generally available from wholesalers, and by prohibiting MAC reimbursement below certain benchmarks. For drugs listed in the FDA Drug Shortages Database, PBMs must reimburse at no less than wholesale acquisition cost. The bill further bars PBMs from requiring extra accreditation beyond state or federal licensing, requires a dedicated contact point for MAC appeals, and sets a floor for reimbursement tied to national average drug acquisition cost or wholesale acquisition cost plus a dispensing fee at least equal to the Medicaid fee-for-service rate, with inflation adjustments every two years beginning in 2026.
The overall sentiment around the bill appears strongly favorable and largely noncontroversial in committee and on the House floor. It passed the House Public Health Committee 7-0, the House Health and Human Services Oversight Committee 13-0, and the House third reading by a wide margin, with only two nays recorded in the voting history provided. The floor transcript reflects no debate before passage, suggesting broad support for the measure.
The main points of contention, based on the bill text, are the increased regulatory burden on PBMs and the higher reimbursement obligations imposed on them. Pharmacies and pharmacy organizations are the primary beneficiaries of the bill’s appeal rights, documentation requirements, and reimbursement floors, while PBMs and insurers may view the measure as restricting pricing flexibility and increasing administrative and payment costs. The bill’s detailed retroactive adjustment rules and prohibition on under-cost reimbursement are likely the most significant operational changes for PBMs.
HB3538 amends 59 O.S. Sections 357 and 360, expanding and clarifying Oklahoma’s PBM regulatory framework. It affects PBMs, insurers, plan sponsors, pharmacies, and pharmacy service administrative organizations by imposing new contract terms, appeal procedures, reimbursement floors, MAC-list standards, and disclosure requirements. The bill also updates statutory references and language, and it takes effect November 1, 2026.
The bill appears to have broad bipartisan or at least cross-chamber support, with unanimous committee votes and an overwhelming House floor vote. The transcript indicates no substantive debate at final passage, which suggests the measure was viewed as a routine or widely accepted PBM reform. The voting pattern points to strong support for pharmacy reimbursement protections and transparency requirements.
The likely controversy centers on the bill’s impact on PBM business practices and reimbursement costs. PBMs may object to the mandated reimbursement minimums, the requirement to accept additional documentation, the short appeal timelines, the retroactive reprocessing rules, and the obligation to provide detailed claim-level data. Pharmacies and pharmacy groups, by contrast, are the parties most likely to support these provisions because they improve appeal rights and reduce the risk of being reimbursed below acquisition cost. Insurers and plan sponsors may also be affected indirectly through higher drug benefit costs.